MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer caught up with Proactive's Andrew Scott following completion of its 50-patient Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment, ArtemiC, on patients diagnosed with COVID-19. Final results are expected to be published next month.
viewMGC Pharmaceuticals Ltd
MGC Pharma 'confident' following completion of ArtemiC Phase II COVID-19 trial
Quick facts: MGC Pharmaceuticals Ltd
Price: 0.088 AUD
ASX:MXC
Market: ASX
Market Cap: $196.14 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
MGC Pharmaceuticals gears up to pursue global growth strategy in 2021
Most read
Health
Emyria appoints global pharmaceutical expert to chair Strategic Advisory Board
4 days, 7 hours ago
Mining
Chalice Mining bolsters board with appointment of highly regarded former Rio...
4 days, 9 hours ago
Mining
Perseus Mining transitions to multi-mine, multi-jurisdictional gold producer...
2 days, 10 hours ago
